310 related articles for article (PubMed ID: 26328016)
1. Stem cell guidance through the mechanistic target of rapamycin.
Maiese K
World J Stem Cells; 2015 Aug; 7(7):999-1009. PubMed ID: 26328016
[TBL] [Abstract][Full Text] [Related]
2. Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR.
Maiese K
Neural Regen Res; 2016 Mar; 11(3):372-85. PubMed ID: 27127460
[TBL] [Abstract][Full Text] [Related]
3. The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.
Maiese K
Biochem Soc Trans; 2018 Apr; 46(2):351-360. PubMed ID: 29523769
[TBL] [Abstract][Full Text] [Related]
4. Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer.
Maiese K
Curr Neurovasc Res; 2017; 14(3):299-304. PubMed ID: 28721811
[TBL] [Abstract][Full Text] [Related]
5. Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus.
Maiese K
Curr Neurovasc Res; 2020; 17(3):327-331. PubMed ID: 32216738
[TBL] [Abstract][Full Text] [Related]
6. Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.
Maiese K
Curr Neurovasc Res; 2017; 14(2):184-189. PubMed ID: 28294062
[TBL] [Abstract][Full Text] [Related]
7. Programming apoptosis and autophagy with novel approaches for diabetes mellitus.
Maiese K
Curr Neurovasc Res; 2015; 12(2):173-88. PubMed ID: 25742566
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes.
Maiese K
Curr Neurovasc Res; 2020; 17(5):765-783. PubMed ID: 33183203
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.
Maiese K
Curr Neurovasc Res; 2016; 13(4):329-340. PubMed ID: 27488211
[TBL] [Abstract][Full Text] [Related]
10. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.
Maiese K
Br J Clin Pharmacol; 2016 Nov; 82(5):1245-1266. PubMed ID: 26469771
[TBL] [Abstract][Full Text] [Related]
11. Picking a bone with WISP1 (CCN4): new strategies against degenerative joint disease.
Maiese K
J Transl Sci; 2016; 1(3):83-85. PubMed ID: 26893943
[TBL] [Abstract][Full Text] [Related]
12. Forkhead transcription factors: new considerations for alzheimer's disease and dementia.
Maiese K
J Transl Sci; 2016 Jul; 2(4):241-247. PubMed ID: 27390624
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs and SIRT1: A Strategy for Stem Cell Renewal and Clinical Development?
Maiese K
J Transl Sci; 2015 Nov; 1(3):55-57. PubMed ID: 26561536
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease.
Maiese K
Curr Neurovasc Res; 2017; 14(1):82-88. PubMed ID: 27897112
[TBL] [Abstract][Full Text] [Related]
15. New Insights for Oxidative Stress and Diabetes Mellitus.
Maiese K
Oxid Med Cell Longev; 2015; 2015():875961. PubMed ID: 26064426
[TBL] [Abstract][Full Text] [Related]
16. Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease.
Maiese K
Neural Regen Res; 2015 Apr; 10(4):518-28. PubMed ID: 26170801
[TBL] [Abstract][Full Text] [Related]
17. Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss.
Maiese K
Curr Neurovasc Res; 2017; 14(4):415-420. PubMed ID: 29149835
[TBL] [Abstract][Full Text] [Related]
18. Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1.
Maiese K
Neural Regen Res; 2021 Mar; 16(3):448-455. PubMed ID: 32985464
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin and diabetes mellitus.
Maiese K
World J Diabetes; 2015 Oct; 6(14):1259-73. PubMed ID: 26516410
[TBL] [Abstract][Full Text] [Related]
20. Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.
Maiese K
Curr Neurovasc Res; 2018; 15(1):81-91. PubMed ID: 29557749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
